对阿尔茨海默氏症痴呆脑病变患者的风险因素的性别差异
Connor John O'Brien1, James Wayne Patterson1, Dami Taiwo Ojo1
1School of Medicine Greenville, University of South Carolina, Greenville, SC, United States.
Frontiers in dementia
|June 10, 2025
概括
这项研究揭示了男性和女性阿尔茨海默氏症痴呆与脑病变 (ADEN) 的独特风险因素. 识别这些性别特异性因素可以改善患者护理和管理策略.
科学领域:
- 神经学 神经学
- 老年学是一门学科.
- 公共卫生 公共卫生
背景情况:
- 阿尔茨海默氏症痴呆症 (AD) 是认知能力下降的主要原因.
- 阿尔茨海默氏症痴呆与脑病变 (ADEN) 是阿尔茨海默氏症的一个严重表现.
- 了解ADEN风险因素中的性别差异对于有针对性的干预至关重要.
研究的目的:
- 为了确定导致性差异的风险因素,在阿尔茨海默氏症痴呆与脑病变 (ADEN).
- 为了比较男性和女性ADEN患者的性别特异性风险概况.
- 为改善ADEN的临床管理提供见解.
主要方法:
- 追溯队列研究分析了2016年2月至2020年8月的数据.
- 包括128,769名AD患者,其中41,266人被诊断为ADEN.
- 单变量和多变量分析以确定ADEN的性别特异性风险因素.
主要成果:
- 男性ADEN患者的高血压,外周血管疾病,心房动,幻觉和创伤性头部损伤的风险增加.
- 女性ADEN患者表现出与骨质疏松症,未指定的癌症,焦虑,尿路感染,上呼吸道感染和胃肠道相关的风险降低.
- 特定的因素,如周围血管疾病和焦虑被确定为性别差异的关键调解者.
结论:
- 对于患有ADEN的男性和女性患者,存在不同的风险因素概况.
- 这些发现凸显了在ADEN管理中性别特定方法的重要性.
- 识别和管理这些性别特异性风险因素可以带来更好的患者结果.
更多相关视频
08:29Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
Published on: December 18, 2016
14.0K
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
7.9K
相关概念视频
01:26Alzheimer's Disease: Overview
451
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
451
01:22Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
01:30Dementia
99
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
99
01:37Neural Regulation
39.2K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.2K